Related references
Note: Only part of the references are listed.A Multi-Targeting, Nucleoside-Modified mRNA Influenza Virus Vaccine Provides Broad Protection in Mice
Alec W. Freyn et al.
MOLECULAR THERAPY (2020)
A Thermostable mRNA Vaccine against COVID-19
Na-Na Zhang et al.
CELL (2020)
A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice
Dorottya Laczko et al.
IMMUNITY (2020)
SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness
Kizzmekia S. Corbett et al.
NATURE (2020)
Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates
Kizzmekia S. Corbett et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
An mRNA Vaccine against SARS-CoV-2-Preliminary Report
L. A. Jackson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses
Ugur Sahin et al.
NATURE (2020)
Viral Emerging Diseases: Challenges in Developing Vaccination Strategies
Maria Trovato et al.
FRONTIERS IN IMMUNOLOGY (2020)
The Opposing Effect of Type I IFN on the T Cell Response by Non-modified mRNA-Lipoplex Vaccines Is Determined by the Route of Administration
Lien Van Hoecke et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2020)
Protection against herpes simplex virus type 2 infection in a neonatal murine model using a trivalent nucleoside-modified mRNA in lipid nanoparticle vaccine
Philip C. LaTourette et al.
VACCINE (2020)
mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials
Robert A Feldman et al.
VACCINE (2019)
A Facile Method for the Removal of dsRNA Contaminant from In Vitro-Transcribed mRNA
Markus Baiersdoerfer et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2019)
Nucleoside-modified mRNA encoding HSV-2 glycoproteins C, D, and E prevents clinical and subclinical genital herpes
Sita Awasthi et al.
SCIENCE IMMUNOLOGY (2019)
Modified mRNA-Based Vaccines Elicit Robust Immune Responses and Protect Guinea Pigs From Ebola Virus Disease
Michelle Meyer et al.
JOURNAL OF INFECTIOUS DISEASES (2018)
Cutting Edge: Protection by Antiviral Memory CD8 T Cells Requires Rapidly Produced Antigen in Large Amounts
Sanda Remakus et al.
JOURNAL OF IMMUNOLOGY (2018)
mRNA vaccines - a new era in vaccinology
Norbert Pardi et al.
NATURE REVIEWS DRUG DISCOVERY (2018)
Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies
Norbert Pardi et al.
NATURE COMMUNICATIONS (2018)
New Kids on the Block: RNA-Based Influenza Virus Vaccines
Francesco Berlanda Scorza et al.
VACCINES (2018)
Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses
Kapil Bahl et al.
MOLECULAR THERAPY (2017)
Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination
Norbert Pardi et al.
NATURE (2017)
Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge
Norbert Pardi et al.
NATURE COMMUNICATIONS (2017)
Modified mRNA Vaccines Protect against Zika Virus Infection (vol 168, pg 1114, 2017)
Justin M. Richner et al.
CELL (2017)
Shortened Intervals during Heterologous Boosting Preserve Memory CD8 T Cell Function but Compromise Longevity
Emily A. Thompson et al.
JOURNAL OF IMMUNOLOGY (2016)
Type I Interferons Interfere with the Capacity of mRNA Lipoplex Vaccines to Elicit Cytolytic T Cell Responses
Ans De Beuckelaer et al.
MOLECULAR THERAPY (2016)
N1-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice
Oliwia Andries et al.
JOURNAL OF CONTROLLED RELEASE (2015)
Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes
Norbert Pardi et al.
JOURNAL OF CONTROLLED RELEASE (2015)
Crosstalk between the Type 1 Interferon and Nuclear Factor Kappa B Pathways Confers Resistance to a Lethal Virus Infection
Daniel Rubio et al.
CELL HOST & MICROBE (2013)
Biodegradable Lipids Enabling Rapidly Eliminated Lipid Nanoparticles for Systemic Delivery of RNAi Therapeutics
Martin A. Maier et al.
MOLECULAR THERAPY (2013)
Maximizing the Potency of siRNA Lipid Nanoparticles for Hepatic Gene Silencing In Vivo
Muthusamy Jayaraman et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2012)
Memory CD8+ T Cells Specific for a Single Immunodominant or Subdominant Determinant Induced by Peptide-Dendritic Cell Immunization Protect from an Acute Lethal Viral Disease
Sanda Remakus et al.
JOURNAL OF VIROLOGY (2012)
Developing mRNA-vaccine technologies
Thomas Schlake et al.
RNA BIOLOGY (2012)
CD94 Is Essential for NK Cell-Mediated Resistance to a Lethal Viral Disease
Min Fang et al.
IMMUNITY (2011)
The development of vaccines: how the past led to the future
Stanley A. Plotkin et al.
NATURE REVIEWS MICROBIOLOGY (2011)
Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA
Katalin Kariko et al.
NUCLEIC ACIDS RESEARCH (2011)
Correlates of Protection Induced by Vaccination
Stanley A. Plotkin
CLINICAL AND VACCINE IMMUNOLOGY (2010)
Age-dependent susceptibility to a viral disease due to decreased natural killer cell numbers and trafficking
Min Fang et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
Survival of lethal poxvirus infection in mice depends on TLR9, and therapeutic vaccination provides protection
Christofer Samuelsson et al.
JOURNAL OF CLINICAL INVESTIGATION (2008)
The orthopoxvirus type IIFN binding protein is essential for virulence and an effective target for vaccination
Ren-Huan Xu et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2008)
Incorporation of Pseudouridine Into mRNA Yields Superior Nonimmunogenic Vector With Increased Translational Capacity and Biological Stability
Katalin Kariko et al.
MOLECULAR THERAPY (2008)
Inflammation directs memory precursor and short-lived effector CD8+ T cell fates via the graded expression of T-bet transcription factor
Nikhil S. Joshi et al.
IMMUNITY (2007)
A genome-wide set of congenic mouse strains derived from DBA/2J on a C57BL/6J background
RC Davis et al.
GENOMICS (2005)
Biosynthesis of the IFN-γ binding protein of ectromelia virus, the causative agent of mousepox
HD Bai et al.
VIROLOGY (2005)
Identification of poxvirus CD8+ T cell determinants to enable rational design and characterization of smallpox vaccines
DC Tscharke et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells
SM Kaech et al.
NATURE IMMUNOLOGY (2003)
A Toll-like receptor recognizes bacterial DNA
H Hemmi et al.
NATURE (2000)
Analysis of host response modifier ORFs of ectromelia virus, the causative agent of mousepox
NH Chen et al.
VIRUS RESEARCH (2000)
Share Paper
